Author

Pilar M. Domínguez

InsermORCID 0000-0002-5775-4351Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

Abdelillah MaaradiD· 1 shared Adarsh Nair· 1 shared Agata Karolina PastorczakiD· 1 shared Aleksandra A. PandyraiD· 1 shared Ana Carolina Bastos Sant'Anna SilvaiD· 1 shared Ari M. MelnickiD· 1 shared Arnaud JacqueliD· 1 shared Arndt BorkhardtiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abdelillah MaaradORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells

Julian Schliehe‐Diecks, Jia‐Wey Tu, Paweł Stachura, Katerina Schaal, Marie Kemkes, Eleni Vasileiou, Nadine Rüchel, Danielle Brandes, Melina Vogt, Thomas Lenz, Adarsh Nair, Stefanie Scheu, Pilar M. Domínguez, Agata Karolina Pastorczak, Karin Nebral, , Sanil Bhatia

This study shows HDAC6 inhibition enhances anti-tumoral immune responses and chemosensitivity in myeloid leukemia cells by upregulating RNase T2 and improving chromatin accessibility.

Cell Death and Disease · Mar 7, 2026Peer-reviewedCell Biology

Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma

Calixte Calaud, Emilio M. Serrano-López, Leonie A. Cluse, Izabela Todorovski, Thomas Mardivirin, Matt R. Teater, Abdelillah Maarad, Noura Tawfic, Peter Fraser, Killian Guiraud, Coralie F Dupont, Corinne Ménigot, Ana Carolina Bastos Sant'Anna Silva, David Yoannidis, Timothy J. Semple, , Pilar M. Domínguez

This study shows that combining a HDAC3 inhibitor with 5-Azacitidine enhances anti-tumor effects against DLBCL in vitro and in vivo, with reduced toxicity compared to single agents.

Blood Neoplasia · Mar 2, 2026Peer-reviewedCancer Biology